$1.11 Billion is the total value of Redmile Group, LLC's 54 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SNSS | Exit | SUNESIS PHARMACEUTICALS INC | $0 | – | -25,000 | -100.0% | -0.01% | – |
| IBB | Exit | ISHARES TRnasdq biotec etf | $0 | – | -1,000 | -100.0% | -0.03% | – |
| WCG | Exit | WELLCARE HEALTH PLANS INC | $0 | – | -4,887 | -100.0% | -0.04% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -25,235 | -100.0% | -0.06% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -137,681 | -100.0% | -0.18% | – |
| PACB | Exit | PACIFIC BIOSCIENCES CALIF IN | $0 | – | -237,977 | -100.0% | -0.20% | – |
| TKAI | Exit | TOKAI PHARMACEUTICALS INC | $0 | – | -215,139 | -100.0% | -0.34% | – |
| EHTH | Exit | EHEALTH INC | $0 | – | -264,942 | -100.0% | -0.72% | – |
| CNXR | Exit | CONNECTURE INC | $0 | – | -943,000 | -100.0% | -0.92% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -234,254 | -100.0% | -0.99% | – |
| BLUE | Exit | BLUEBIRD BIO INC | $0 | – | -102,227 | -100.0% | -1.02% | – |
| UHS | Exit | UNIVERSAL HLTH SVCS INCcl b | $0 | – | -135,270 | -100.0% | -1.64% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -93,865 | -100.0% | -1.93% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -87,523 | -100.0% | -1.98% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -258,305 | -100.0% | -1.98% | – |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -368,615 | -100.0% | -3.78% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -342,349 | -100.0% | -4.17% | – |
| RAD | Exit | RITE AID CORP | $0 | – | -6,038,734 | -100.0% | -4.94% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.